Mesoblast (MESO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Mesoblast (MESO) is Neutral.

The composite score behind that read is -0.03, weighing +0.08 of bullish evidence against -0.19 bearish.

Mesoblast last closed at $14.29, +3.93% on the session.

Against the IVW growth benchmark the position is +3.13% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

12 graded predictions for MESO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Mesoblast is classified under Health Care / Biotechnology, with a market capitalisation of $1.79B.

StockMap tracks Mesoblast as the 102nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Mesoblast ranks 131st of 381 in the group, against a group median of -0.08.